Mithrl has announced a $20 million Series A, led by Obvious Ventures, with participation from Headline, AGI House, and several pharmaceutical executives. The announcement brings up an increasingly important challenge in...read more
Category - Precision medicine
A Single-Cell Map of the Human Immune System Across Lifespan
The status of the human immune system is heavily involved in both disease defense and healthy aging or its converse. At enligtenbio we have an interest in understanding human immune function and how immune changes link...read more
Tempus Acquires Personalis and Raises the Stakes in the MRD Market
The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more
When “Anonymous” Isn’t: The UK Biobank Data Exposure and the Limits of Health Data Privacy
The UK Biobank data exposure highlights a growing risk in modern health research: sensitive data is not only vulnerable to breaches, but to systemic leakage through normal scientific practices. This raises urgent...read more
